Are larger increases in bone mineral density during alendronate therapy associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis . Fracture Intervention Trial Research Group?
Women with increases of > or =3% in BMD during the first 1 or 2 years of alendronate treatment had the lowest incidence of new vertebral fractures. These findings suggest that, among women taking antiresorptive agents, greater increases in BMD are associated with lower risk of new vertebral fractures.
Aqueous VEGF concentration is increased in eyes with glaucoma.